Castanet: Princeton mushroom research and development facility officially opens, sells first grow of psilocybin mushrooms

By Casey Richardson

 

Castanet – Changing lives with shrooms

 

A new cultivation facility that is hoping to change lives with psychedelic mushrooms had their grand opening on Friday in Princeton, after being awarded a dealer’s license in February by Health Canada.

Optimi Health Corp. is a Canadian company that researches, develops and grows psilocybin-producing mushrooms and functional mushrooms. The company has been building its two adjacent 10,000 square foot facilities since August 2020.

The grand opening event and reception invited investors, stakeholders and the residents of Princeton to take a tour through the facilities. Princeton Mayor Spencer Coyne and UK Conservative MP Crispin Blunt spoke in support of the facility.

Businesses have been recently receiving approval from Health Canada to farm psychedelic mushrooms, make psilocybin and sell the compound to drug-makers, or to doctors to give to patients.

Todd Henderson, the head of cultivation at Optimi, said that as a Metis with Cree heritage, he was drawn into joining the company to carry on work he learned at a young age as a part of his culture.

“Mushrooms have been a part of our culture for hundreds of years, this is something I picked up early and I’ve just carried it on. I’m the next generation doing it,” he said.

“This is a natural medicine. They’re creating medicine synthetically, and giving it to people to do exactly what this can do. The potential for psilocybin is untouched.”

Approval of providing the psychedelic compound that comes from magic mushrooms started after Health Canada launched a program in January that allows physicians to request government approval for patients to access psilocybin.

Without that approval, using psilocybin is currently illegal.

“There’s really been medical curiosity, but then also historical evidence of where it can make a big difference in anxiety, depression and PTSD. and a life existentialism and addictions I mean, it used to be routinely used,” Bill Ciprick, Optimi CEO said.

There are still stigmas that exist around the use of psychedelics.

“That was there was a reason why in the 70s, that the Nixon government put in place the Controlled Substances Act, which then kind of got spread to 140 countries around the world. Some of it was warranted, some of it was not warranted. And quite frankly, most of the bad press was with LSD,” Ciprick added.

“Psilocybin is the most studied psychedelic molecule right now, around the world. And there are literally hundreds of trials that are being done, and more forthcoming.”

Ciprick said there needs to be more outcome data and studies on the psilocybin-producing mushrooms to give that comfort level heading forward into introducing a larger market for the product.

It’s not only psychedelic mushrooms that are being grown, Optimi also has its hand in functional mushrooms that will go into their nutraceutical side.

“I’m excited that we’re the first doing it. I think it’s incredible that here in Princeton, BC .This is the pinnacle of this medicine coming to fruition naturally,” Henderson said.

The team has been focused on creating an environment that can be perfectly controlled for production.

The psilocybin mushrooms are headed to clinical trials, drug companies and medical facilities.

“I’m excited that we pulled our first crop down. It’s already sold to Halucenex in Nova Scotia, we’re excited about that. We have other deals on the books already,” Henderson said.

“It’s one thing to to put an amazing facility in place, but then to actually concentrate that with our first sale of the first batch of psilocybin mushrooms. I think for everybody, myself included, it was a very proud moment,” Ciprick added.

Optimi hopes to see others have a chance to see the work they’re doing and their commitment to being a standing natural GMP psilocybin producer.

“I want people to be excited about natural medicine. Don’t be afraid of psilocybin, we’re not growing it as a recreational drug here, we’re growing it, GMP (good manufacturing practices) to be used in medical practice,“ Henderson said.

In their 10,000 square foot facility, production of natural GMP psilocybin for use by approved entities in clinical trials and individuals granted access by Health Canada will be given through legal mechanisms such the Special Access Program and Section 56 exemptions to the Controlled Drugs and Substances Act.

Source: Castanet

ABOUT OPTIMI

(CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Products do not contain psilocybin

Get news & updates directly to your inbox.
Thank you for your interest in our investor presentation.

Please sign up here and we will send the presentation to your inbox.
Interested In Optimi? Let's Talk.